PubRank

Atanasio Pandiella

Author PubWeight™ 72.20‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell 2002 2.54
2 Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 2008 1.95
3 Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011 1.79
4 The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006 1.67
5 Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2005 1.66
6 Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 2002 1.64
7 Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 2011 1.43
8 New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008 1.41
9 In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2009 1.38
10 HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2012 1.37
11 Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 2009 1.35
12 Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol 2010 1.27
13 Multifunctional role of Erk5 in multiple myeloma. Blood 2005 1.22
14 Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 2005 1.21
15 Neuregulins and cancer. Clin Cancer Res 2008 1.21
16 Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 2008 1.17
17 Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem 2003 1.16
18 Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007 1.16
19 CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica 2012 1.14
20 The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica 2008 1.13
21 Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008 1.11
22 Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin. Cancer Res 2005 1.09
23 Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 2010 1.07
24 ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. J Immunol 2006 1.06
25 Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation. Clin Cancer Res 2010 1.01
26 Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J 2002 1.01
27 Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem 2006 1.00
28 Multisite phosphorylation of Erk5 in mitosis. J Cell Sci 2010 0.95
29 Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica 2008 0.95
30 Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue. Stem Cells 2013 0.95
31 Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. Clin Cancer Res 2008 0.95
32 Deficient spindle assembly checkpoint in multiple myeloma. PLoS One 2011 0.94
33 Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005 0.93
34 Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int J Oncol 2012 0.93
35 A new method for detecting TNF-alpha-secreting cells using direct-immunofluorescence surface membrane stainings. J Immunol Methods 2002 0.92
36 Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications. Mol Cancer Ther 2012 0.92
37 Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J Pathol 2006 0.91
38 Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem 2004 0.91
39 Overexpression of HER2 signaling to WAVE2-Arp2/3 complex activates MMP-independent migration in breast cancer. Breast Cancer Res Treat 2010 0.90
40 Mechanism of apoptosis induced by IFN-alpha in human myeloma cells: role of Jak1 and Bim and potentiation by rapamycin. Cell Signal 2006 0.90
41 ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy. PLoS One 2009 0.89
42 Erk5 is activated and acts as a survival factor in mitosis. Cell Signal 2007 0.89
43 Do we have to change the way targeted drugs are developed? J Clin Oncol 2010 0.88
44 The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev 2012 0.88
45 Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cell Signal 2007 0.88
46 Personalized therapies in the cancer "omics" era. Mol Cancer 2010 0.88
47 Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cell Signal 2013 0.87
48 Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leuk Res 2010 0.86
49 The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008 0.85
50 Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One 2012 0.85
51 The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant 2008 0.85
52 Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res 2013 0.85
53 Targeting HER receptors in cancer. Curr Pharm Des 2013 0.85
54 A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab Invest 2004 0.85
55 Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014 0.83
56 Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. Am J Clin Oncol 2006 0.83
57 ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia 2013 0.82
58 The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function. Mol Biol Cell 2006 0.81
59 A modular approach to trim cellular targets in anticancer drug discovery. Bioorg Med Chem Lett 2011 0.81
60 Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015 0.81
61 RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs 2012 0.80
62 Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer Metastasis Rev 2014 0.79
63 Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica 2011 0.78
64 Enhancement of antiproliferative activity by molecular simplification of catalpol. Bioorg Med Chem 2010 0.78
65 Novel tyrosine kinase inhibitors in the treatment of cancer. Curr Drug Targets 2009 0.77
66 Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells. J Biochem 2005 0.77
67 N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity. Biochem J 2005 0.77
68 Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. Curr Cancer Drug Targets 2017 0.76
69 Mitotic arrest induced by a novel family of DNA topoisomerase II inhibitors. J Med Chem 2010 0.76
70 Transautocrine signaling by membrane neuregulins requires cell surface targeting, which is controlled by multiple domains. J Biol Chem 2011 0.75
71 Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. Mol Cancer Ther 2014 0.75
72 Mitogen-activated protein kinase routes as targets in the action of diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells. Mol Cancer Ther 2002 0.75
73 β-Lapachone analogs with enhanced antiproliferative activity. Eur J Med Chem 2012 0.75
74 Erratum: Achilles' heel of triple negative cancer. Oncoscience 2014 0.75